Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06412068

A Prospective Study: Sintilimab and R-CHOP in PMBCL Treatment

Primary Mediastinal Large B Cell Lymphoma Clinical Trial

Official title:
A Prospective, Single-arm, Multi-center Exploratory Study on the First-line Treatment of Primary Mediastinal Large B-cell Lymphoma ( PMBCL ) With Sintilimab Combined With R-CHOP Regimen

Clinical Trial Summary

The purpose of this multi-center, single arm, phase Ⅱ clinical trail is to evaluate the efficacy and toxicity of sintilimab combined with R-CHOP regimen as first-line treatment for primary mediastinal large B-cell Lymphoma (PMBCL)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06412068
Study type Interventional
Source Sun Yat-sen University
Contact Hua Wang, MD
Phone +86-15920352412
Email wagnhua@sysucc.org.cn
Status Not yet recruiting
Phase Phase 2
Start date June 1, 2024
Completion date June 1, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Recruiting NCT05934448 - Pembro Plus CAR T-cell Therapy in R/R in PMBCL Phase 2
Recruiting NCT05326243 - Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma Phase 1/Phase 2
Completed NCT04323657 - TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Phase 1/Phase 2
Terminated NCT04844086 - RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies Phase 1
Active, not recruiting NCT04067414 - Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma Phase 1
Active, not recruiting NCT04464200 - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Phase 1
Recruiting NCT05653271 - ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies Phase 1
Enrolling by invitation NCT04488354 - Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T Phase 1
Recruiting NCT04705129 - Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL Phase 2
Recruiting NCT05377307 - Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Withdrawn NCT04503538 - Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity N/A
Active, not recruiting NCT04542824 - Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL Phase 1/Phase 2
Active, not recruiting NCT04450069 - CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies Phase 1
Recruiting NCT05544019 - Study of SGR-1505 in Mature B-Cell Neoplasms Phase 1
Active, not recruiting NCT01516567 - Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation Phase 2